KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Account Payables (2018 - 2025)

Historic Change in Account Payables for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $2.9 million.

  • Esperion Therapeutics' Change in Account Payables rose 12271.73% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.7 million, marking a year-over-year increase of 39428.87%. This contributed to the annual value of $12.4 million for FY2024, which is 4325.88% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Change in Account Payables is $2.9 million, which was up 12271.73% from $2.6 million recorded in Q2 2025.
  • Esperion Therapeutics' Change in Account Payables' 5-year high stood at $27.8 million during Q1 2025, with a 5-year trough of -$21.6 million in Q1 2021.
  • For the 5-year period, Esperion Therapeutics' Change in Account Payables averaged around $1.4 million, with its median value being $2.6 million (2025).
  • As far as peak fluctuations go, Esperion Therapeutics' Change in Account Payables plummeted by 224273.79% in 2022, and later soared by 90707.25% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Change in Account Payables (Quarter) stood at -$3.3 million in 2021, then skyrocketed by 236.99% to $4.5 million in 2022, then increased by 23.02% to $5.5 million in 2023, then soared by 69.04% to $9.3 million in 2024, then crashed by 68.82% to $2.9 million in 2025.
  • Its Change in Account Payables stands at $2.9 million for Q3 2025, versus $2.6 million for Q2 2025 and $27.8 million for Q1 2025.